Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa Follow-up Trial
NCT00357734Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2005
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gefitinib in lung cancer and breast cancer, sponsored by AstraZeneca. Primary endpoints: Number of Serious Adverse Events up to 120 months, Number of Serious Adverse Events Related to ZD1839 up to 120 months and 2 more. Started Jan 2005; status: completed.
02
Drugs
03
Conditions
lung cancerbreast cancer
Beyond the preview
Go deeper on NCT00357734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00357734.